25K Stock Overview A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Karyopharm Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Karyopharm Therapeutics Historical stock prices Current Share Price US$0.63 52 Week High US$1.52 52 Week Low US$0.57 Beta 0.072 1 Month Change 6.71% 3 Month Change -15.63% 1 Year Change -13.56% 3 Year Change -91.70% 5 Year Change -95.73% Change since IPO -97.93%
Recent News & Updates
Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024 Jan 15 Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025
New major risk - Share price stability Dec 31
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications Dec 10
Karyopharm Therapeutics Inc. Provides Endometrial Cancer Program Update Dec 03
Karyopharm Therapeutics Inc. Appoints Kristin Abate as Chief Accounting Officer Nov 21 See more updates
Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024 Jan 15 Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025
New major risk - Share price stability Dec 31
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications Dec 10
Karyopharm Therapeutics Inc. Provides Endometrial Cancer Program Update Dec 03
Karyopharm Therapeutics Inc. Appoints Kristin Abate as Chief Accounting Officer Nov 21
Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.30 loss in 3Q 2023) Nov 05
Karyopharm Therapeutics Inc. Narrows Earnings Guidance for the Full Year of 2024 Nov 05 Karyopharm Therapeutics Inc. to Report Q3, 2024 Results on Nov 05, 2024
Karyopharm Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5450(a)(1) Sep 18
New minor risk - Market cap size Aug 21
Second quarter 2024 earnings released: EPS: US$0.20 (vs US$0.29 loss in 2Q 2023) Aug 07 Karyopharm Therapeutics Inc. Revises Earnings Guidance for the Full Year 2024 Aug 07
Karyopharm Therapeutics Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 01
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from Russell 3000 Index Jul 03 Karyopharm Therapeutics Inc. announced that it expects to receive $100 million in funding May 10
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024 May 09
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.30 loss in 1Q 2023) May 08
Karyopharm Therapeutics Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting Apr 25
Karyopharm Therapeutics Inc., Annual General Meeting, May 29, 2024 Apr 21
New minor risk - Shareholder dilution Apr 19
Full year 2023 earnings released: US$1.25 loss per share (vs US$2.02 loss in FY 2022) Mar 01
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024 Feb 29
Karyopharm Therapeutics Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023 Jan 08 Karyopharm Therapeutics Receives Non-Compliance Notice From Nasdaq Dec 13
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients Dec 11
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors Dec 08 Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023
Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.45 loss in 3Q 2022) Nov 03
Karyopharm Therapeutics Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
New minor risk - Market cap size Oct 26
Karyopharm Therapeutics Inc. Appoints Zhen Su to Its Board of Directors Sep 02
Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.62 loss in 2Q 2022) Aug 03
Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023 Aug 03
Karyopharm Therapeutics Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer Jul 26
Karyopharm Therapeutics Inc. Initiates Pivotal Phase 3 Clinical Trial (XPORT-MF-034) to Assess Efficacy and Safety of Once-Weekly Selinexor 60Mg in Combination with Ruxolitinib in JAKi-Naïve Patients with Myelofibrosis Jun 29
Karyopharm Therapeutics Inc. Revises Earnings Guidance for the Year 2023 May 05
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.53 loss in 1Q 2022) May 05
President recently sold €94k worth of stock Mar 09
Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Full Year 2023 Feb 16
Full year 2022 earnings released: US$2.02 loss per share (vs US$1.65 loss in FY 2021) Feb 16
Karyopharm Therapeutics Inc. to Report Q4, 2022 Results on Feb 15, 2023 Feb 09
Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
Karyopharm Therapeutics Inc. Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022 Dec 13 Karyopharm Therapeutics Inc. announced that it expects to receive $165.000003 million in funding from a group of investors Dec 06
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.45 loss per share (vs US$0.69 loss in 3Q 2021) Nov 05
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fiscal Year 2022 Nov 04
Karyopharm Therapeutics Inc. and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis Nov 01
Karyopharm Therapeutics Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Second quarter 2022 earnings released: US$0.62 loss per share (vs US$0.71 loss in 2Q 2021) Aug 05
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2022 Aug 05 Karyopharm Therapeutics Inc. to Report Q2, 2022 Results on Aug 04, 2022
Karyopharm Therapeutics Inc. and Menarini Group Receives Full Marketing Authorisation from the European Commission for NEXPOVIO Jul 22
Karyopharm Therapeutics Inc. Receives Health Canada Authorization for XPOVIO® (selinexor) Jun 09
The European Myeloma Network and Karyopharm Therapeutics Inc. Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study May 26
Karyopharm Therapeutics Inc. and Menarini Group Receive Positive Chmp Opinion for Nexpovio® (Selinexor) for the Treatment of Patients with Refractory Multiple Myeloma May 21
First quarter 2022 earnings released: US$0.53 loss per share (vs US$0.77 loss in 1Q 2021) May 06
High number of new directors Apr 27
Karyopharm Therapeutics Inc., Annual General Meeting, May 19, 2022 Apr 09
Karyopharm Therapeutics Inc Announces Executive Changes Mar 30
Michael G. Kauffman, M.D., Ph.D. Notifies Karyopharm Therapeutics Inc. of His Resignation from the Board of Directors Mar 29
Co-Founder recently sold €57k worth of stock Mar 09
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer Mar 03
Co-Founder recently sold €97k worth of stock Feb 25
Karyopharm Therapeutics Inc. Announces Changes to Its Clinical Leadership Team Feb 24
Co-Founder recently sold €58k worth of stock Feb 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Karyopharm Therapeutics Inc Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer Feb 09
Karyopharm Therapeutics Inc. to Report Q4, 2021 Results on Feb 08, 2022 Feb 03
Karyopharm Therapeutics Inc. Announces Dosing of First Patient in A New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis Dec 07
Karyopharm Therapeutics Inc. Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer Dec 03
Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.73 loss in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.71 loss per share (vs US$0.63 loss in 2Q 2020) Aug 06
Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS Jun 09
Karyopharm Announces XPOVIO(selinexor) Availability in Additional Strength Tablets Jun 04
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma Jun 03
Karyopharm Therapeutics Inc. Announces Open Enrollment At Participating Hospitals In Europe For A Phase 3 Maintenance Study Evaluating Selinexor In Patients With Endometrial Cancer After Combination Chemotherapy May 27
Insider recently bought €165k worth of stock May 12 Shareholder Returns 25K DE Biotechs DE Market 7D 2.1% -3.0% 2.3% 1Y -13.6% -5.3% 11.9%
See full shareholder returns
Return vs Market: 25K underperformed the German Market which returned 11.9% over the past year.
Price Volatility Is 25K's price volatile compared to industry and market? 25K volatility 25K Average Weekly Movement 12.6% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 25K's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 25K's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Show more Karyopharm Therapeutics Inc. Fundamentals Summary How do Karyopharm Therapeutics's earnings and revenue compare to its market cap? 25K fundamental statistics Market cap €80.72m Earnings (TTM ) -€83.97m Revenue (TTM ) €142.49m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 25K income statement (TTM ) Revenue US$148.44m Cost of Revenue US$16.72m Gross Profit US$131.72m Other Expenses US$219.20m Earnings -US$87.48m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.69 Gross Margin 88.73% Net Profit Margin -58.93% Debt/Equity Ratio -165.4%
How did 25K perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 00:22 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Peter Lawson Barclays Ying Huang BofA Global Research
Show 16 more analysts 
